临床试验/NCT01839955

NCT01839955已完成1 期

A Phase I Study of Erlotinib in Combination With Quinacrine in Patients With Advanced Non-Small-Cell Lung Cancer

Neelesh Sharma MD PhD1 个研究点分布在 1 个国家目标入组 12 人开始时间: 2013年9月最近更新: 2016年10月31日

适应症

干预措施

试验速览

阶段: 1 期
状态: 已完成
发起方
入组人数: 12
试验地点: 1
主要终点: Maximum tolerated dose (MTD) of quinacrine dihydrochloride in combination of erlotinib hydrochloride determined by dose-limiting toxicities

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This phase I trial studies the side effects and best dose of quinacrine dihydrochloride when given together with erlotinib hydrochloride and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as quinacrine dihydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib hydrochloride together with quinacrine dihydrochloride may kill more tumor cells

详细描述

PRIMARY OBJECTIVES:

I. To assess the safety and tolerability of the combination of erlotinib (erlotinib hydrochloride) and quinacrine (quinacrine dihydrochloride) in patients with advanced non-small-cell lung cancer.

II. To determine the recommended Maximum Tolerated Dose (MTD) of the combination of erlotinib and quinacrine in patients with advanced non-small-cell lung cancer.

SECONDARY OBJECTIVES:

I. To describe the dose limiting toxicity of the erlotinib and quinacrine combination.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients must have histologically or cytologically confirmed incurable malignancy that is surgically unresectable locally advanced, recurrent, or metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC). Patients with adenocarcinoma, squamous cell carcinoma, large cell carcinoma and sarcomatoid carcinoma will be eligible.
•Patients must have received at least one platinum-containing regimen for the treatment of advanced or metastatic disease (except for EGFR-mutant patients). Prior maintenance therapy is allowed and will be considered as the same line of therapy when continued without discontinuation after initiation of a treatment regimen. NSCLC with documented EGFR mutation will be eligible after progression on an EGFR-TKI alone. NSCLC with other molecular targets, such as fusion gene involving the anaplastic lymphoma kinase (ALK) gene (such as echinoderm microtubule associated protein like 4 [EML4]-ALK) or ROS-1 will be eligible if they have progressed on targeted agents (ALK inhibitor) and chemotherapy or are not a candidate for chemotherapy. Adjuvant/neoadjuvant chemotherapy or chemoradiation is considered a line of therapy if < 12 months have elapsed between the last dose and the date of recurrence. Combined treatment with chemotherapy and radiation constitutes a single regimen.
•Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
•Life expectancy of ≥ 12 weeks, in the opinion of and as documented by the investigator
•Hemoglobin ≥ 9.0 g/dl (transfusion and/or growth factor support allowed)
•Absolute neutrophil count (ANC) ≥ 1,500/mcL
•Platelet count ≥ 100 x 10^9 L
•Alkaline phosphatase < 2.5 X institutional upper limit of normal (in subjects with no liver metastasis and < 5.0 upper limit of normal [ULN] in subjects with liver metastasis)
•Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X institutional upper limit of normal (in subjects with no liver metastasis and < 5.0 ULN in subjects with liver metastasis)
•Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min
•Serum total bilirubin ≤ 1.5 x ULN OR total bilirubin ≤ 4.0 ULN with direct bilirubin ≤ 1.5 x ULN in patients with well documented Gilbert syndrome
•Patients who are receiving therapeutic anticoagulation with heparin are allowed to participate provided that no prior evidence of underlying abnormality exists in these parameters. Patients on warfarin are eligible provided they are on stable doses of warfarin and there is close monitoring of INR.
•Resolution of any toxic effects of prior therapy (including radiotherapy) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, grade ≤ 1 (with the exception of alopecia and ≤ grade 2 neuropathy); subject must have recovered from significant surgery-related complications
•Women of childbearing potential must have a negative pregnancy test performed within 48 hours prior to the start of the study drug
•Women of child-bearing potential and men must agree to use adequate contraception (double barrier method of birth control or abstinence) prior to study entry, for the duration of study participation and for 90 days after completing the last investigational drug dose; should a woman become pregnant or suspect that she is pregnant while she or her partner is participating in this study, she should inform the treating physician immediately
•Subjects must have the ability to understand and the willingness to sign a written informed consent document

排除标准

•Patients with previous anti-cancer chemotherapy, immunotherapy or investigational agents ≤ 3 weeks prior to the first day of study defined treatment. NSCLC patients with EGFR mutation can enroll within 7 days of discontinuing EGFR-TKI. Palliative radiation < 1 week before the start of treatment (lesions subjected to radiotherapy may not be used as target lesions). Patients who receive gamma knife radiosurgery for brain metastases within 1 week prior to treatment start.
•Patients with unknown status of EGFR mutation (only for patients with adenocarcinoma histology)
•Patients that have had major surgery ≤ 3 weeks or minor surgery (e.g. talc pleurodesis, excisional biopsy, etc) ≤ 1 week prior to the first day of study defined treatment.
•History of cardiac disease: congestive heart failure defined as class II to IV per New York Heart Association (NYHA) classification; active coronary artery disease (CAD); previously diagnosed bradycardia or other cardiac arrhythmia defined as ≥ grade 2 according to NCI-CTCAE (version 4.0), or uncontrolled hypertension; myocardial infarction occurred within 6 months prior to study entry (myocardial infarction occurred > 6 months prior to study entry is permitted)
•Patients with clinically unstable central nervous system (CNS) metastasis (to be enrolled in the study, subjects must have confirmation of stable disease by magnetic resonance imaging [MRI] or computed tomography [CT] scan within 4 weeks of the first day of study defined treatment and have CNS metastases well controlled by steroids, anti-epileptics or other symptom-relieving medications)
•Patients with significant gastrointestinal disorder that, in the opinion of the investigator, could interfere with absorption of quinacrine and/or erlotinib (eg, Crohn's disease, small or large bowel resection, malabsorption syndrome)
•Patients with any known contraindication to treatment with, including hypersensitivity to quinacrine or erlotinib
•Patients with active clinically serious infections defined as ≥ grade 2 according to NCI CTCAE, version 4.0
•Patients with substance abuse, medical, psychological or social conditions that may, in the opinion of the Investigator, interfere with the patient's participation in the study or evaluation of the study results
•Any other condition that is unstable or which could jeopardize the safety of the patient and his/her protocol compliance
•History of incurable malignancy other than NSCLC within the 5 years prior to start of treatment, with the exceptions of adequately treated intraepithelial carcinoma of the cervix uteri; prostate carcinoma with a prostate-specific antigen value <0.2 ng/mL; or basal or squamous-cell carcinoma of the skin.
•Pregnant or breastfeeding women and adults of reproductive potential not employing an effective method of birth control are excluded from this study because quinacrine is category N agent with the potential for teratogenic or abortifacient effects; these potential risks may also apply to other agents used in this study
•Patients with previously known infection with human immunodeficiency virus (HIV) or active viral hepatitis are ineligible because of the potential for pharmacokinetic interactions with quinacrine; (diagnostic testing for these infections will be done only if clinically indicated)
•Patients with known Glucose-6-phosphate deficiency, psoriasis, porphyria and psychosis (quinacrine may exacerbate the symptoms of these disorders)

研究组 & 干预措施

Arm I (Dose Escalation Group)

Experimental

Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.

干预措施: erlotinib hydrochloride (Drug)

Arm I (Dose Escalation Group)

Experimental

Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.

干预措施: quinacrine dihydrochloride - Escalation dose (Drug)

Arm I (Dose Escalation Group)

Experimental

Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.

干预措施: laboratory biomarker analysis (Other)

Arm I (Dose Escalation Group)

Experimental

Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.

干预措施: pharmacological study (Other)

Arm II (Extension Group)

Experimental

Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.

干预措施: erlotinib hydrochloride (Drug)

Arm II (Extension Group)

Experimental

Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.

干预措施: laboratory biomarker analysis (Other)

Arm II (Extension Group)

Experimental

Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.

干预措施: pharmacological study (Other)

Arm II (Extension Group)

Experimental

Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.

干预措施: quinacrine dihydrochloride - Extension dose (Drug)

结局指标

主要结局

Maximum tolerated dose (MTD) of quinacrine dihydrochloride in combination of erlotinib hydrochloride determined by dose-limiting toxicities

时间窗: 28 days

Progression Free Survival (PFS)

时间窗: Date of randomization to the date of disease progression or the date of death, assessed up to 2 years

Estimated by Kaplan-Meier method and the difference between two treatment arms will be evaluated by log-rank test.

次要结局

Pharmacokinetic parameters(after 2 months (2 cycles))
Disease stabilization rate (complete response, partial response and stable disease)(Up to 2 years)
Baseline expression of intracellular inhibitor of the nuclear factor kappa B (IkappaB) or NFkappaB gene signature in determining survival or response(Baseline up to 2 years)
Objective tumor response rate (ORR) (complete response and partial response) evaluated by revised Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria(Up to 2 years)
Overall survival (OS)(Date of randomization to the date of death, assessed up to 2 years)

研究者

发起方

Neelesh Sharma MD PhD

申办方类型

Other

责任方

Sponsor Investigator

主要研究者

Neelesh Sharma MD PhD

Principal Investigator

Case Comprehensive Cancer Center

研究点 (1)

Loading locations...

相似试验

已完成

1 期

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeFLT3 Gene Mutation NegativeFLT3 Internal Tandem Duplication PositiveRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaRefractory Myelodysplastic Syndrome

NCT01892371M.D. Anderson Cancer Center73

已完成

1 期

NCT00397384National Cancer Institute (NCI)43

已完成

2 期

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by SurgeryRecurrent Renal Cell CarcinomaStage III Renal Cell CancerStage IV Renal Cell CancerType 1 Papillary Renal Cell CarcinomaType 2 Papillary Renal Cell Carcinoma

NCT01688973National Cancer Institute (NCI)55

已完成

2 期

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell CarcinomaRenal Cell Carcinoma

NCT00353301University of Colorado, Denver25

招募中

1 期

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia

NCT03661307M.D. Anderson Cancer Center73